Santa Ana Bio, an Alameda, CA-based precision immunology company, raised $168M in combined Series A and B funding.
Founding investor Versant Ventures led the Series A round and was joined by TPG’s Life Science Innovations fund and GV. The $125M Series B round was led by GV, with participation from all existing investors as well as new investors Access Biotechnology, Andreessen Horowitz (a16z) Bio + Health and RTW.
The company intends to use the funds to expand operations and its R&D sector.
Led by Peter Emtage, Ph.D., CEO and board member, Santa Ana Bio is a biotechnology company developing a pipeline of therapeutics and leveraging its multi-omics platform to improve the precisions medicines. Its platform, based on transcriptomics and proteomics, addresses the limitations of commercial therapeutics. It aims to expand the reach of precision medicines to different cell types and pathways, to benefit more patients with autoimmune and inflammatory diseases.
Since the company was launched in 2022, Santa Ana has advanced three programs that are poised to enter the clinic starting next year.
SAB01 inhibits c-Kit, a validated target on the mast cells that drive a variety of allergic diseases.
SAB03 agonizes PD-1, a clinically validated target in rheumatoid arthritis.
Santa Ana’s SAB05 ADC program employs a novel technology for antibody-glucocorticoid conjugates.
FinSMEs
13/06/2024